Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,071–1,080 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1071
- Medicine slug
- nebivolol
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 41
- Source count
- 41
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 41
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 41 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f5766c0-e1fa-4805-a32c-523182310ad5 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aad20a92-bc2e-4624-b588-c6d40facd3a7 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ce89dc5-018d-db40-e063-6294a90a9722 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a5e1bd8-f2b6-42e6-972d-09418528cd63 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abb0546f-08dd-4354-8b41-d17065b52c24 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6c5abdd-bc2d-4ed6-8ca2-8a94c406ed0e (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2639abce-a5ca-4b7f-99d7-026ab3233aaa (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef3b8ec9-0cec-40d4-824f-fc2b6cafd39a (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a81733f-abb2-4090-a1e1-cbca356821e8 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5953f23b-2f41-4b49-bcdb-1691f4ffa35f (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:126de78c-fb3d-4a53-9aaf-f2dfe1ac2a2f (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1762bbb-b5be-48a7-8101-bb736f28845a (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:202d5142-6180-4d48-9a9f-1bd6992fc49b (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b8ad213-1dc8-454e-a524-075685c0e1a8 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e43a4e2-574e-4f4a-804d-e346b4edd2f1 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ebcc539-efe0-4545-bd83-37c20de7efb0 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a64dad-6922-4737-ab46-98c185782b38 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:156c41be-551b-46ab-86a8-52f6f70a4689 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19d20396-ade8-400e-94f4-69913637d051 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d4b1e1a-d5c3-4bdc-860d-387e8fd0b389 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f85d7b19-51d9-47d9-bd7b-13d45ad7759b (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f20fda1a-437d-4812-b519-a26684c96c6d (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b5631c-44a3-05b4-e063-6394a90aeb7d (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:451cdd6e-13b4-402f-8a44-cdf5f7433a49 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb47560d-9e35-4b0f-b12b-6ea478684a5b (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9d8edb5-5312-ad38-e053-2995a90a7154 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51d3f12f-94cc-4f58-94d3-61990e16adfc (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afb38a32-1520-4fd9-ac00-cf6825dfe70a (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6606db5-3937-4e90-9870-3cbfa4ec909e (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5418f2b2-3e23-4e7a-b4df-36a1515c9a12 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f0bd0b4-ee17-46bb-b4e2-8ca0ea0e0489 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9bad35e-cd48-48f1-93ca-46490dbf70a8 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e54ddb53-542b-4183-8950-5b3947ecead0 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdd7a3c5-d3dd-4a89-97d7-642f96eda21b (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77fb6b5f-7bfe-4fc8-980c-fc688ac9837a (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90d4ea48-7831-4cb0-8796-1ed79407c363 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ca84bf1-511d-480d-ba3d-0eef00ddad3e (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fecef8fc-b66b-4133-b66f-8d6b72750622 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78c20341-4fbf-4c78-9817-03e7e0072f82 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3745fc9d-cd3f-4877-bef0-81d9a9a05786 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e9e1048-b5ea-4d6a-9363-3ee0d059e088 (opens source in a new tab)
Nebivolol label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
Projected row 1072
- Medicine slug
- nefazodone
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
20%
- Numeric value
- 20
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ff7db5-aaf9-4c3c-86e6-958ebf16b60f (opens source in a new tab)
Nefazodone label
Version not recorded · Effective date not recorded
Pharmacokinetics Nefazodone is rapidly and completely absorbed but is subject to extensive metabolism, so that its absolute bioavailability is low, about 20%, and variable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bd4c34a-4f43-4c84-8b98-1d074cba97d5 (opens source in a new tab)
Nefazodone label
Version not recorded · Effective date not recorded
Pharmacokinetics Nefazodone is rapidly and completely absorbed but is subject to extensive metabolism, so that its absolute bioavailability is low, about 20%, and variable.
Projected row 1073
- Medicine slug
- nefazodone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
2 to 4 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ff7db5-aaf9-4c3c-86e6-958ebf16b60f (opens source in a new tab)
Nefazodone label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur at about one hour and the half-life of nefazodone is 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bd4c34a-4f43-4c84-8b98-1d074cba97d5 (opens source in a new tab)
Nefazodone label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur at about one hour and the half-life of nefazodone is 2 to 4 hours.
Projected row 1074
- Medicine slug
- nefazodone
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
2 to 4 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ff7db5-aaf9-4c3c-86e6-958ebf16b60f (opens source in a new tab)
Nefazodone label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur at about one hour and the half-life of nefazodone is 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bd4c34a-4f43-4c84-8b98-1d074cba97d5 (opens source in a new tab)
Nefazodone label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur at about one hour and the half-life of nefazodone is 2 to 4 hours.
Projected row 1075
- Medicine slug
- nefazodone
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
0.22 to 0.87 L/kg
- Numeric value
- 0.22
- Unit
- L/kg
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ff7db5-aaf9-4c3c-86e6-958ebf16b60f (opens source in a new tab)
Nefazodone label
Version not recorded · Effective date not recorded
In humans the volume of distribution of nefazodone ranges from 0.22 to 0.87 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bd4c34a-4f43-4c84-8b98-1d074cba97d5 (opens source in a new tab)
Nefazodone label
Version not recorded · Effective date not recorded
In humans the volume of distribution of nefazodone ranges from 0.22 to 0.87 L/kg.
Projected row 1076
- Medicine slug
- nelarabine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
3.2 hours
- Numeric value
- 3.2
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d0e1b59-bd1e-4c6e-9a95-e8143ee076bf (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f9051de-5c4d-4c0f-8c19-e15214498cca (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1cc1580-50d9-4b9b-a002-1fc6686a9515 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ad6056-0e71-4e7c-842a-a5f87649bdcd (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2a08758-9a9d-49a2-a498-9da109045ee9 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21919314-5c25-49ab-beba-099983ed4a71 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d556a9e7-310b-41dc-99f8-a281fe7da3fe (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cb23281-93ca-40b8-b8e0-c57dd4298322 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc401b06-4e3b-413e-a854-3e031c433862 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fffa5d75-0dba-4ad7-a252-5f60fa28489a (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e425731e-626b-4141-a997-fb85e077c2a4 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57275b05-f40f-7298-5a5e-93594bc41437 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f60da70f-2f9e-421d-a277-95b1edb57a71 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:651bf4d2-75b0-4a60-8014-7006ffe61084 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are rapidly eliminated from plasma with a mean half-life of 18 minutes and 3.2 hours, respectively, in adult patients.
Projected row 1077
- Medicine slug
- nelarabine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
25%
- Numeric value
- 25
- Unit
- %
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d0e1b59-bd1e-4c6e-9a95-e8143ee076bf (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f9051de-5c4d-4c0f-8c19-e15214498cca (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1cc1580-50d9-4b9b-a002-1fc6686a9515 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ad6056-0e71-4e7c-842a-a5f87649bdcd (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro, and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2a08758-9a9d-49a2-a498-9da109045ee9 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro, and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21919314-5c25-49ab-beba-099983ed4a71 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d556a9e7-310b-41dc-99f8-a281fe7da3fe (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro, and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cb23281-93ca-40b8-b8e0-c57dd4298322 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro, and binding is independent of nelarabine or ara-G concentrations up to 600 µM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc401b06-4e3b-413e-a854-3e031c433862 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fffa5d75-0dba-4ad7-a252-5f60fa28489a (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e425731e-626b-4141-a997-fb85e077c2a4 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 µM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57275b05-f40f-7298-5a5e-93594bc41437 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 mcM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f60da70f-2f9e-421d-a277-95b1edb57a71 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro, and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:651bf4d2-75b0-4a60-8014-7006ffe61084 (opens source in a new tab)
Nelarabine label
Version not recorded · Effective date not recorded
Nelarabine and ara-G are not substantially bound to human plasma proteins (< 25%) in vitro , and binding is independent of nelarabine or ara-G concentrations up to 600 μM.
Projected row 1078
- Medicine slug
- neostigmine-methylsulfate
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 31
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
15 to 25%
- Numeric value
- 15
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6448229c-e650-47ba-bb00-cba3604502c5 (opens source in a new tab)
Neostigmine Methylsulfate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Protein binding of neostigmine to human serum albumin ranges from 15 to 25%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0e11e4c-41c3-4874-b567-579db655fba3 (opens source in a new tab)
Neostigmine Methylsulfate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Protein binding of neostigmine to human serum albumin ranges from 15 to 25%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12575d1a-a2c2-37b2-0dcf-31e58bbc2a10 (opens source in a new tab)
Neostigmine Methylsulfate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Protein binding of neostigmine to human serum albumin ranges from 15 to 25%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:088f96eb-20b8-48f8-ac83-329f75a44ce1 (opens source in a new tab)
Neostigmine Methylsulfate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Protein binding of neostigmine to human serum albumin ranges from 15 to 25%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0b509c3-8dc8-48cc-b7a8-16b93ad706c6 (opens source in a new tab)
Neostigmine Methylsulfate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Protein binding of neostigmine to human serum albumin ranges from 15 to 25%.
Projected row 1079
- Medicine slug
- nevirapine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
90%
- Numeric value
- 90
- Unit
- %
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:effb86cc-4b80-4fac-aaa3-9f373b3d0f7d (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption and Bioavailability Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy volunteers and in adults with HIV-1 infection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dfe86aa-ea5d-48d2-94a8-1a5506055d70 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption and Bioavailability Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy volunteers and in adults with HIV-1 infection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f065674-4719-4c79-ba0d-549040d77f17 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption and Bioavailability Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy volunteers and in adults with HIV-1 infection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61409678-d2f6-42cd-b03d-b26b11b39641 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption and Bioavailability Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy volunteers and in adults with HIV-1 infection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd628db-4076-4fe0-8323-9cc33ae92e42 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption and Bioavailability Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy volunteers and in adults with HIV-1 infection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f6c3eed-2a5d-46ed-9a7c-59715f338a15 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption and Bioavailability Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy volunteers and in adults with HIV-1 infection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6e93829-7024-48f6-8023-da6ff27dfc0a (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption and Bioavailability Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy volunteers and in adults with HIV-1 infection.
Projected row 1080
- Medicine slug
- nevirapine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
45 hours
- Numeric value
- 45
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:effb86cc-4b80-4fac-aaa3-9f373b3d0f7d (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25-30 hours following multiple dosing with 200-400 mg per day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dfe86aa-ea5d-48d2-94a8-1a5506055d70 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25 to 30 hours following multiple dosing with 200 to 400 mg per day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f065674-4719-4c79-ba0d-549040d77f17 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25 to 30 hours following multiple dosing with 200 to 400 mg/day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61409678-d2f6-42cd-b03d-b26b11b39641 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25 to 30 hours following multiple dosing with 200 to 400 mg per day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2620b114-f53f-44f1-8708-697e86343090 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25-30 hours following multiple dosing with 200-400 mg per day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd628db-4076-4fe0-8323-9cc33ae92e42 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25 to 30 hours following multiple dosing with 200 to 400 mg per day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f6c3eed-2a5d-46ed-9a7c-59715f338a15 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25 to 30 hours following multiple dosing with 200 to 400 mg per day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:690da74b-2481-47fc-93ae-8340e0caf0a4 (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25-30 hours following multiple dosing with 200-400 mg per day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6e93829-7024-48f6-8023-da6ff27dfc0a (opens source in a new tab)
Nevirapine label
Version not recorded · Effective date not recorded
Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25-30 hours following multiple dosing with 200-400 mg per day.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1070Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.